Luc Tanguay - Theratechnologies President, Chief Executive Officer, Director
TH Stock | CAD 1.79 0.02 1.13% |
CEO
Mr. Luc Tanguay is President, Chief Executive Officer, Director of Theratechnologies, Inc. Mr. Tanguay was active in the biotechnology industry for over 20 years. As a member of our senior management since 1996, he has contributed to our growth by facilitating access to public and private capital funding. A member of the board of directors since 1993, he has held various management positions since joining the Company. Prior to joining us, Mr. Tanguay had a career in investment banking at National Bank Financial Inc. Mr. Tanguay obtained his M. Sc. Finance from the University of Sherbrooke. since 2014.
Age | 57 |
Tenure | 10 years |
Address | 2015 Peel Street, Montreal, QC, Canada, H3A 1T8 |
Phone | 514 336 7800 |
Web | https://www.theratech.com |
Theratechnologies Management Efficiency
The company has return on total asset (ROA) of (0.0455) % which means that it has lost $0.0455 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (11.1686) %, meaning that it generated substantial loss on money invested by shareholders. Theratechnologies' management efficiency ratios could be used to measure how well Theratechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 4th of May 2024, Return On Equity is likely to grow to 1.39, while Return On Tangible Assets are likely to drop (0.44). At this time, Theratechnologies' Non Current Assets Total are very stable compared to the past year. As of the 4th of May 2024, Other Current Assets is likely to grow to about 10 M, while Total Assets are likely to drop about 65.2 M.Management Performance
Return On Equity | -11.17 | ||||
Return On Asset | -0.0455 |
Theratechnologies Leadership Team
Elected by the shareholders, the Theratechnologies' board of directors comprises two types of representatives: Theratechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Theratechnologies. The board's role is to monitor Theratechnologies' management team and ensure that shareholders' interests are well served. Theratechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Theratechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
MarieNoel Colussi, Vice President - Finance | ||
Luc Tanguay, President, Chief Executive Officer, Director | ||
Jovan Antunovic, Senior Vice President and Chief Commercial Office | ||
Conor Walshe, General Manager - Theratechnologies Europe Limited | ||
Sheila Frame, Independent Director | ||
Paul Lvesque, CEO President | ||
Philippe Dubuc, Chief Financial Officer, Senior Vice President | ||
Paul Levesque, President, Chief Executive Officer, Director | ||
Andrew Molson, Independent Director | ||
Gerald Lacoste, Independent Director | ||
LLB LLM, General Secretary | ||
Dawn Svoronos, Independent Chairman of the Board | ||
Pierre Perazzelli, Vice President - Pharmaceutical Development | ||
LLB BA, VP Affairs | ||
Denis Boucher, Vice President - Communications and Corporate Affairs | ||
H MSc, Vice Resources | ||
Chantal Placais, Executive Assistant | ||
Lyne Fortin, Senior Vice President Chief Commercial Officer | ||
Christian Marsolais, Senior Vice President - Scientific Affairs and Alliances | ||
John Leasure, Global Officer | ||
Paul Pommier, Independent Director | ||
Gilles Cloutier, Independent Director | ||
Gary Littlejohn, Independent Director | ||
JeanDenis Talon, Independent Director | ||
Elif McDonald, Director Relations | ||
Jocelyn Lafond, Vice President - Legal Affairs, Corporate Secretary | ||
Alain Trudeau, Independent Director | ||
MBA MBA, Senior CFO | ||
Dale Weil, Independent Director |
Theratechnologies Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Theratechnologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -11.17 | ||||
Return On Asset | -0.0455 | ||||
Profit Margin | (0.23) % | ||||
Operating Margin | (0.14) % | ||||
Current Valuation | 102.07 M | ||||
Shares Outstanding | 45.98 M | ||||
Shares Owned By Insiders | 6.28 % | ||||
Shares Owned By Institutions | 50.72 % | ||||
Number Of Shares Shorted | 22.73 K | ||||
Price To Earning | (52.28) X |
Currently Active Assets on Macroaxis
LAAC | Lithium Americas Corp | |
F | Ford Motor | |
CHPT | ChargePoint Holdings | |
AXL | American Axle Manufacturing | |
ICLN | iShares Global Clean |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theratechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Theratechnologies Stock, please use our How to Invest in Theratechnologies guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Theratechnologies Stock analysis
When running Theratechnologies' price analysis, check to measure Theratechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theratechnologies is operating at the current time. Most of Theratechnologies' value examination focuses on studying past and present price action to predict the probability of Theratechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theratechnologies' price. Additionally, you may evaluate how the addition of Theratechnologies to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |